DelMar Pharmaceuticals (NASDAQ:DMPI) Shares Up 6.5%

DelMar Pharmaceuticals Inc (NASDAQ:DMPI)’s stock price shot up 6.5% during mid-day trading on Wednesday . The company traded as high as $0.66 and last traded at $0.66, 350,500 shares changed hands during trading. A decline of 6% from the average session volume of 374,793 shares. The stock had previously closed at $0.62.

A number of research analysts recently commented on the company. Dawson James restated a “buy” rating on shares of DelMar Pharmaceuticals in a research note on Thursday, July 11th. ValuEngine cut DelMar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 2nd. Finally, Maxim Group started coverage on shares of DelMar Pharmaceuticals in a report on Friday, September 6th. They set a “buy” rating for the company.

The stock has a market capitalization of $1.63 million, a P/E ratio of -0.12 and a beta of 1.13. The company’s 50-day moving average is $1.10 and its two-hundred day moving average is $1.13.

DelMar Pharmaceuticals Company Profile (NASDAQ:DMPI)

DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.

See Also: Are Wall Street analysts’ stock ratings worth following?

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.